Research Interest: Biomarkers associated with organ rejection
after transplantation; Immunogenetic factors in disease; Molecular
markers influencing ischemia reperfusion injury
Research Interest: Cell
culture, Stem cell culture and differentiation into 3 germ layers
(human, mouse and rat ESCs and iPSCs ), mesenchymal stem cells (human
umbilical cord stem cells, canine adipose tissue stem cells, rat bone
marrow stem cells) and various cancer cell lines (N2a neuroblastoma
cells, A375, A549), neural stem cells (mouse, human, rat and marmoset),
3D stem cell culture. Molecular Biology -PCR, Q-PCR, plasmid DNA
isolation, RNA isolation, western blotting, co-immunoprecipitation,
immunocytochemistry, micro array analysis, ChIP, bisulfite modification,
gene expression analysis using Qlucore and DAVID, transfection (neon
and lipofectamine), lentiviral transduction. Microscopy-Extensive
experience in confocal and fluorescence microscopy. Animal Handling-Rats
and mice, rat embryo dissection, microinjection (blastocyst injection),
chimera formation, rat umbilical cord and embryonic fibroblast
isolation and bone marrow isolation.
A senior staff scientist has more than 10 years of experience in hematology and stem cell research. My research interest covers in vitro and in vivo functional study of leukemia-causing mutation and development of viral vectors for gene therapy. I have received my PhD from The Institute of Cancer Research, London, UK with a focus on mouse modelling of Mixed Lineage Leukaemia gene amplification. Then, I became a post-doctoral research scientist at the University of Oxford, UK with a focus on functional characterization of splicing factor mutations in MDS. After that I worked as a Gene editing Senior scientist in Adaptimmune Ltd for T-cell immunotherapy. At the moment I am a staff scientist at St Jude Children Research Hospital Vector Development Core specialized in development of viral vector for gene therapy.
PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia.
Chase A, Pellagatti A, Singh S, Score J, Tapper WJ, Lin F, Hoade Y, Bryant C, Trim N, Yip BH, Zoi K, Rasi C, Forsberg LA, Dumanski JP, Boultwood J, Cross NCP.
Leukemia. 2018 Dec 20. doi: 10.1038/s41375-018-0340-5. [Epub ahead of print]
L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del(5q) myelodysplastic syndrome patients.
Bello E, Kerry J, Singh S, Yip BH, Kušec R, Killick S, Raynaud S, Boultwood J, Pellagatti A.
Haematologica. 2018 Nov;103(11):e496-e500. doi: 10.3324/haematol.2018.190447. Epub 2018 Jun 14. No abstract available.
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.
Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.
Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia.
Yip BH, Tsai CT, Rane JK, Vetharoy W, Anguita E, Dong S, Caligiuri MA, So CWE.
Haematologica. 2017 Aug;102(8):e300-e304. doi: 10.3324/haematol.2016.161406. Epub 2017 May 18. No abstract available.
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.
Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.
Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
Dolatshad H, Pellagatti A, Liberante FG, Llorian M, Repapi E, Steeples V, Roy S, Scifo L, Armstrong RN, Shaw J, Yip BH, Killick S, Kušec R, Taylor S, Mills KI, Savage KI, Smith CW, Boultwood J.
Leukemia. 2016 Dec;30(12):2322-2331. doi: 10.1038/leu.2016.149. Epub 2016 May 23.
Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
Yip BH, Dolatshad H, Roy S, Pellagatti A, Boultwood J.
Curr Pharm Des. 2016;22(16):2333-44. Review.
ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
Valletta S, Dolatshad H, Bartenstein M, Yip BH, Bello E, Gordon S, Yu Y, Shaw J, Roy S, Scifo L, Schuh A, Pellagatti A, Fulga TA, Verma A, Boultwood J.
Oncotarget. 2015 Dec 29;6(42):44061-71. doi: 10.18632/oncotarget.6392.
Application of genome editing technologies to the study and treatment of hematological disease.
Pellagatti A, Dolatshad H, Yip BH, Valletta S, Boultwood J.
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, Przychodzen B, Sahgal N, Kanapin AA, Lockstone H, Scifo L, Vandenberghe P, Papaemmanuil E, Smith CW, Campbell PJ, Ogawa S, Maciejewski JP, Cazzola M, Savage KI, Boultwood J.
Leukemia. 2015 Aug;29(8):1798. doi: 10.1038/leu.2015.178. No abstract available.
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, Przychodzen B, Sahgal N, Kanapin AA, Lockstone H, Scifo L, Vandenberghe P, Papaemmanuil E, Smith CW, Campbell PJ, Ogawa S, Maciejewski JP, Cazzola M, Savage KI, Boultwood J.
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF.
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16127-32. doi: 10.1073/pnas.1311055110. Epub 2013 Sep 16.
Mixed lineage leukemia protein in normal and leukemic stem cells.
Yip BH, So CW.
Exp Biol Med (Maywood). 2013 Mar;238(3):315-23. doi: 10.1177/1535370213480717. Review.
Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.
Yip BH, Vuppusetty C, Attwood M, Giagounidis A, Germing U, Lamikanra AA, Roberts DJ, Maciejewski JP, Vandenberghe P, Mecucci C, Wainscoat JS, Pellagatti A, Boultwood J.
Leukemia. 2013 Aug;27(8):1760-3. doi: 10.1038/leu.2013.20. Epub 2013 Jan 22. No abstract available.
Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34⁺ progenitor cells.
Davies C, Yip BH, Fernandez-Mercado M, Woll PS, Agirre X, Prosper F, Jacobsen SE, Wainscoat JS, Pellagatti A, Boultwood J.
Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.
Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T, Pérez C, Killick S, McDonald EJ, Odero MD, Agirre X, Prósper F, Calasanz MJ, Wainscoat JS, Boultwood J.
PLoS One. 2012;7(8):e42334. doi: 10.1371/journal.pone.0042334. Epub 2012 Aug 9.
Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.
Yip BH, Pellagatti A, Vuppusetty C, Giagounidis A, Germing U, Lamikanra AA, Roberts DJ, Fernandez-Mercado M, McDonald EJ, Killick S, Wainscoat JS, Boultwood J.
Leukemia. 2012 Sep;26(9):2154-8. doi: 10.1038/leu.2012.82. Epub 2012 Mar 20. No abstract available.
Each step from submission to publication was handled efficiently. The review comments were accurate which increased the value of our revised manuscript. I will certainly publish more works with Peertechz.More
C
cantrella caralynn
It was found that each step in the submission and publishing process was handled efficiently. The reviewers were clearly experts in the field and our revised manuscript was dealt with value.More
S
Samantha Wyatt
The entire review and production process for the article has been handled with remarkable professionalism and efficiency. As the editor, I can appreciate the enormous organizational effort and discipline shown.More
MUSHTAQ CHALKOO
Tomorrow is a search of today and if we research,we add an another day,that is how the time pulls on and on.Science keeps on changing its facies and thus paradigm and makes our living interesting and awesome.The knowledge of science needs to be dissipated to the progeny for better living ahead and the way we do that is through scientific journals published by different publication houses.Being associated with peertechz publications has been a wonderful experience.i have enjoyed the true spirit of scientific spice serving the organisation as an editor.It is author friendly,and makes the publication process for you very easy taking care not to jeopardise the standards of true science.I would suggest the research scholars and young scientists to associate with this publication house ,submit your reseach to brighten your career ahead in science.let us keep up the spirit of spreading the true science to the world ahead.More
Dr Shivaji Jadhav
Wonderful ..process and indeed very good way in terms of communication and i recommend for publishing with this publishers...Great support.More